[go: up one dir, main page]

IL139934A0 - Pyrrole substituted 2-indolinone derivatives and pharmaceutical compositions containing the same - Google Patents

Pyrrole substituted 2-indolinone derivatives and pharmaceutical compositions containing the same

Info

Publication number
IL139934A0
IL139934A0 IL13993499A IL13993499A IL139934A0 IL 139934 A0 IL139934 A0 IL 139934A0 IL 13993499 A IL13993499 A IL 13993499A IL 13993499 A IL13993499 A IL 13993499A IL 139934 A0 IL139934 A0 IL 139934A0
Authority
IL
Israel
Prior art keywords
same
pharmaceutical compositions
compositions containing
indolinone derivatives
pyrrole substituted
Prior art date
Application number
IL13993499A
Other languages
English (en)
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc filed Critical Sugen Inc
Publication of IL139934A0 publication Critical patent/IL139934A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13993499A 1998-05-29 1999-05-28 Pyrrole substituted 2-indolinone derivatives and pharmaceutical compositions containing the same IL139934A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8731098P 1998-05-29 1998-05-29
US11610699P 1999-01-15 1999-01-15
PCT/US1999/012069 WO1999061422A1 (en) 1998-05-29 1999-05-28 Pyrrole substituted 2-indolinone protein kinase inhibitors

Publications (1)

Publication Number Publication Date
IL139934A0 true IL139934A0 (en) 2002-02-10

Family

ID=26776832

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13993499A IL139934A0 (en) 1998-05-29 1999-05-28 Pyrrole substituted 2-indolinone derivatives and pharmaceutical compositions containing the same
IL139934A IL139934A (en) 1998-05-29 1999-05-28 History 2 - Indulinone converted to pyrrole and pharmaceutical preparations containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL139934A IL139934A (en) 1998-05-29 1999-05-28 History 2 - Indulinone converted to pyrrole and pharmaceutical preparations containing them

Country Status (23)

Country Link
US (2) US6395734B1 (xx)
EP (2) EP1082305A4 (xx)
JP (1) JP4528440B2 (xx)
KR (1) KR100743287B1 (xx)
CN (1) CN1250526C (xx)
AR (1) AR018408A1 (xx)
AU (1) AU759226B2 (xx)
BR (1) BR9910792A (xx)
CA (1) CA2314156C (xx)
CO (1) CO5031249A1 (xx)
DK (1) DK2020408T3 (xx)
EA (1) EA005032B1 (xx)
ES (1) ES2429573T3 (xx)
HU (1) HUP0103617A2 (xx)
IL (2) IL139934A0 (xx)
NO (1) NO318083B1 (xx)
NZ (1) NZ508815A (xx)
PL (1) PL344477A1 (xx)
PT (1) PT2020408E (xx)
SK (1) SK287132B6 (xx)
TR (1) TR200003514T2 (xx)
TW (1) TWI229073B (xx)
WO (1) WO1999061422A1 (xx)

Families Citing this family (266)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906093B2 (en) * 1995-06-07 2005-06-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6316429B1 (en) * 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
US6051593A (en) * 1997-06-20 2000-04-18 Sugen, Inc. 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
HUP0103617A2 (hu) * 1998-05-29 2002-02-28 Sugen, Inc. Protein kinázt gátló, pirrolilcsoporttal helyettesített 2-indolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
BR9916223A (pt) 1998-12-17 2001-09-04 Hoffmann La Roche 4-ariloxindóis como inibidores de cinases de proteìna jnk
US6153634A (en) * 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
JP2002532492A (ja) 1998-12-17 2002-10-02 エフ．ホフマン−ラ ロシュ アーゲー サイクリン−依存性キナーゼ、特にｃｄｋ２のインヒビターとしての４−アルケニル（及びアルキニル）オキシドール
US20030119895A1 (en) * 1998-12-23 2003-06-26 Pharmacia Corporation Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
US6689806B1 (en) * 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
EP1233943B1 (en) * 1999-11-24 2011-06-29 Sugen, Inc. Ionizable indolinone derivatives and their use as ptk ligands
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
PT1255536E (pt) * 1999-12-22 2006-09-29 Sugen Inc Derivados de indolinona para a modulacao da tirosina proteina cinase de tipo c-kit
US6339100B1 (en) 1999-12-29 2002-01-15 The Trustees Of Columbia University In The City Of New York Methods for inhibiting mastocytosis
ES2269156T3 (es) * 1999-12-30 2007-04-01 Sugen, Inc. Compuestos de heteroarilidenil-3-indolinona para modular la actividad de proteina-quinasas y para el uso en quimioterapia del cancer.
PT1255752E (pt) * 2000-02-15 2007-10-17 Pharmacia & Upjohn Co Llc Inibidores de proteína quinases: 2-indolinonas substituídas com pirrolo
US20020028828A1 (en) 2000-05-02 2002-03-07 Chung-Chen Wei (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
MY128450A (en) * 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
EP1294688A2 (en) 2000-06-02 2003-03-26 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
US6635640B2 (en) 2000-06-30 2003-10-21 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
WO2002055517A2 (en) 2000-12-20 2002-07-18 Jingrong Cui 4-(hetero)aryl substituted indolinones
SV2007000775A (es) 2001-01-05 2007-03-15 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2002070478A1 (en) 2001-03-06 2002-09-12 Astrazeneca Ab Indolone derivatives having vascular-damaging activity
WO2002081466A1 (en) 2001-04-09 2002-10-17 Sugen, Inc. Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CA2448076A1 (en) * 2001-05-24 2002-11-28 Masahiko Hayakawa 3-quinoline-2-(1h)-ylideneindolin-2-one derivatives
PE20030062A1 (es) * 2001-05-30 2003-02-08 Sugen Inc Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
US7727731B2 (en) 2001-06-29 2010-06-01 Ab Science Potent, selective and non toxic c-kit inhibitors
JP2004537536A (ja) 2001-06-29 2004-12-16 アブ サイエンス アレルギー疾患を治療するためのチロシンキナーゼ阻害剤の使用方法
ATE343415T1 (de) 2001-06-29 2006-11-15 Ab Science Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
CA2452390A1 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating bone loss
DK1401415T3 (da) 2001-06-29 2006-10-16 Ab Science Anvendelse af N-phenyl-2-pyrimidinamin-derivater til behandling af inflammatoriske sygdomme
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
MXPA04003385A (es) 2001-10-10 2005-04-11 Sugen Inc Derivados de 3-?4-substituido con heterociclilo)-pirrol-2-ilmetilidene?-2-indolinona como inhibidores de cinasa.
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
ES2247411T3 (es) * 2001-12-27 2006-03-01 Theravance, Inc. Derivados de indolinona utiles como inhibidores de la proteina kinasa.
JP2005527511A (ja) 2002-03-01 2005-09-15 ファイザー インコーポレイテッド 抗血管形成剤として有用なチエノピリジンのインドリル−尿素誘導体およびその使用法
EP1501357A4 (en) * 2002-05-06 2009-10-21 Genentech Inc USE OF VEGF FOR THE TREATMENT OF BONE DEFECTS
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
EP2662211A1 (en) 2002-06-24 2013-11-13 Tufts University Silk biomaterials and methods of use thereof
US20050032871A1 (en) * 2002-09-03 2005-02-10 Sugen, Inc. Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors
CA2506546A1 (en) 2002-11-15 2004-06-17 Exelixis, Inc. Kinase modulators
AR042042A1 (es) * 2002-11-15 2005-06-08 Sugen Inc Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
AU2003284572A1 (en) * 2002-11-22 2004-06-18 Yamanouchi Pharmaceutical Co., Ltd. 2-oxoindoline derivatives
JP4879492B2 (ja) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド 疾患の治療のためのキナーゼ阻害剤
SI1585743T1 (sl) 2002-12-19 2007-08-31 Pfizer Spojine 2-(1H-indazol-6-ilamino)-benzamida kot inhibitorji protein-kinaz, uporabnih pri zdravljenju očesnih bolezni
CN103265477B (zh) 2003-02-26 2017-01-11 苏根公司 作为蛋白激酶抑制剂的氨基杂芳基化合物
US7157577B2 (en) * 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
US20040266843A1 (en) * 2003-03-07 2004-12-30 Sugen, Inc. Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
JP4698596B2 (ja) 2003-04-10 2011-06-08 タフツ ユニバーシティー 濃縮された水性シルクフィブロイン溶液およびそれらの使用
DK1648998T3 (en) 2003-07-18 2015-01-05 Amgen Inc Specific binding agents for hepatocyte growth factor
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
EP1653946A4 (en) * 2003-08-06 2007-04-04 Sugen Inc 3-CYCLOPENTYLIDENE-1,3-DIHYDROINDOL-2-ONES GEOMETRICALLY LIMITED AS POWERFUL INHIBITORS OF PROTEIN KINASES
ATE412655T1 (de) 2003-08-29 2008-11-15 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
KR20060123184A (ko) 2003-10-24 2006-12-01 쉐링 악티엔게젤샤프트 인돌리논 유도체, 및 암과 같은 질환 상태의 치료에있어서의 이들의 용도
WO2005051919A1 (en) * 2003-11-26 2005-06-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
JP4503022B2 (ja) 2003-12-23 2010-07-14 ファイザー・インク 新規キノリン誘導体
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 免疫増強用の化合物
CN101014365B (zh) 2004-07-16 2011-04-13 辉瑞产品公司 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
PL1786785T3 (pl) 2004-08-26 2010-08-31 Pfizer Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
GT200500321A (es) 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
JP2008521900A (ja) 2004-11-30 2008-06-26 アムジエン・インコーポレーテツド キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
ATE477495T1 (de) 2005-03-16 2010-08-15 Osi Pharm Inc Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
WO2006105488A2 (en) 2005-03-31 2006-10-05 Agensys, Inc. Antibodies and related molecules that bind to 161p2f10b proteins
EP2444421A1 (en) 2005-04-26 2012-04-25 Pfizer Inc. P-Cadherin antibodies
EP1883403A4 (en) * 2005-04-29 2011-02-16 Univ Ohio State Res Found KERATINOCYTE GROWTH FACTOR RECEPTOR TYROSINE-SPECIFIC INHIBITORS FOR THE PREVENTION OF CANCER METASTASE
CN101517068B (zh) 2005-09-07 2017-02-08 安进弗里蒙特公司 活化素受体样激酶‑1的人单克隆抗体
JP5055284B2 (ja) 2005-09-20 2012-10-24 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー インシュリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
US20080108664A1 (en) 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR101452520B1 (ko) 2006-01-27 2014-10-21 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 피롤로[3,2-ｃ]피리딘-4-온 2-인돌린온 단백질 키나제 억제제
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
ES2353482T3 (es) 2006-02-10 2011-03-02 Amgen, Inc Formas hidrato de amg706.
KR100647350B1 (ko) * 2006-04-03 2006-11-23 김상민 시밍장치
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
EP2010521A1 (en) 2006-04-19 2009-01-07 Novartis Ag Indazole compounds and methods for inhibition of cdc7
MX2008013990A (es) 2006-05-09 2009-01-29 Pfizer Prod Inc Derivados de cicloalquilamino acidos.
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
WO2008118133A2 (en) 2006-09-26 2008-10-02 Trustees Of Tufts College Silk microspheres for encapsulation and controlled release
US20100113421A1 (en) * 2006-10-06 2010-05-06 Williams Theresa M Non-nucleoside reverse transcriptase inhibitors
EP2125781A2 (en) 2006-12-20 2009-12-02 Amgen Inc. Substituted heterocycles and methods of use
WO2008086014A2 (en) 2007-01-09 2008-07-17 Amgen Inc. Bis-aryl amide derivatives useful for the treatment of cancer
MX2009008531A (es) 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
US9102916B2 (en) 2007-02-27 2015-08-11 Trustees Of Tufts College Tissue-engineered silk organs
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
EP2851091B1 (en) 2007-04-13 2017-12-27 Dana-Farber Cancer Institute, Inc. Methods for treating cancer resistant to ERBB therapeutics
US9808557B2 (en) 2007-08-10 2017-11-07 Trustees Of Tufts College Tubular silk compositions and methods of use thereof
EP3330292A1 (en) 2007-08-21 2018-06-06 Amgen, Inc Human c-fms antigen binding proteins
WO2009030270A1 (en) * 2007-09-03 2009-03-12 Novartis Ag Dihydroindole derivatives useful in parkinson's disease
UY31545A1 (es) 2007-12-20 2009-08-03 Nuevos derivados de 2-carboxamida cianoaminourea, sus sales y profarmacos farmacéuticamente aceptables, procesos de preparacion y aplicaciones
US8993615B2 (en) * 2008-08-08 2015-03-31 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
JP5836125B2 (ja) 2008-10-16 2015-12-24 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用
CN101397295B (zh) * 2008-11-12 2012-04-25 深圳微芯生物科技有限责任公司 作为组蛋白去乙酰化酶抑制剂的2-吲哚满酮衍生物、其制法和用途
WO2010090764A1 (en) 2009-02-09 2010-08-12 Supergen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20100222381A1 (en) 2009-02-27 2010-09-02 Hariprasad Vankayalapati Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US20110076271A1 (en) 2009-07-13 2011-03-31 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
EP2459191A1 (en) 2009-07-31 2012-06-06 OSI Pharmaceuticals, LLC Mtor inhibitor and angiogenesis inhibitor combination therapy
WO2011027249A2 (en) 2009-09-01 2011-03-10 Pfizer Inc. Benzimidazole derivatives
JP2013504595A (ja) 2009-09-11 2013-02-07 ジェネンテック， インコーポレイテッド 抗癌剤に対する応答の可能性が増加した患者を同定するための方法
MX2012002909A (es) 2009-09-17 2012-04-19 Hoffmann La Roche Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
WO2011073521A1 (en) 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
WO2011078312A1 (ja) 2009-12-25 2011-06-30 大鵬薬品工業株式会社 肝細胞癌患者に対する化学療法の治療効果予測方法
WO2011078311A1 (ja) 2009-12-25 2011-06-30 大鵬薬品工業株式会社 肝細胞癌治療のための抗腫瘍剤又は術後補助化学療法剤
JP5745283B2 (ja) 2010-02-12 2015-07-08 ファイザー・インク ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６Ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンの塩および多形体
WO2011109584A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
CN104689314B (zh) 2010-06-16 2018-02-02 高等教育联邦系统-匹兹堡大学 内质蛋白的抗体及其用途
WO2011161217A2 (en) 2010-06-23 2011-12-29 Palacký University in Olomouc Targeting of vegfr2
CN103180737A (zh) 2010-07-19 2013-06-26 霍夫曼-拉罗奇有限公司 鉴定响应抗癌疗法的可能性升高的患者的方法
WO2012010549A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
SG187592A1 (en) 2010-07-23 2013-03-28 Univ Boston Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
ES2543151T3 (es) 2010-10-20 2015-08-17 Pfizer Inc Derivados de 2-piridina como moduladores del receptor Smoothened
AU2012213080B2 (en) 2011-01-31 2014-03-27 Novartis Ag Novel heterocyclic derivatives
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
MX2013010871A (es) 2011-03-23 2014-01-31 Amgen Inc Inhibidores dobles triciclicos fusionados de cdk 4/6 y flt3.
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
ES2724801T3 (es) 2011-04-19 2019-09-16 Pfizer Combinaciones de anticuerpos anti-4-1BB y anticuerpos inductores de ADCC para el tratamiento del cáncer
US10335519B2 (en) 2011-04-20 2019-07-02 Trustees Of Tufts College Dynamic silk coatings for implantable devices
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
PT3409278T (pt) 2011-07-21 2020-12-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de proteína cinase heterocíclicos
WO2013025939A2 (en) 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
CA2847540C (en) 2011-09-22 2016-05-17 Pfizer Inc. Pyrrolopyrimidine and purine derivatives
WO2013050725A1 (en) 2011-10-04 2013-04-11 King's College London Ige anti -hmw-maa antibody
PH12014500912A1 (en) 2011-10-28 2014-06-09 Novartis Ag Novel purine derivatives and their use in the treatment of disease
BR112014011115A2 (pt) 2011-11-08 2017-06-13 Pfizer métodos para tratamento de distúrbios inflamatórios usando anticorpos anti-m-csf
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
HK1205953A1 (en) 2012-03-20 2015-12-31 Trustees Of Tufts College Silk reservoirs for drug delivery
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP2015512944A (ja) 2012-04-13 2015-04-30 トラスティーズ・オブ・タフツ・カレッジＴｒｕｓｔｅｅｓ Ｏｆ Ｔｕｆｔｓ Ｃｏｌｌｅｇｅ 絹マイクロスフェアを調製するための方法および組成物
RU2642463C2 (ru) 2012-04-20 2018-01-25 Аннцзи Фармасьютикал Ко., Лтд. Циклопропанкарбоксилатные эфиры пуриновых аналогов
US10213432B2 (en) 2012-05-16 2019-02-26 Novartis Ag Dosage regimen for a PI-3 kinase inhibitor
WO2014012101A1 (en) 2012-07-13 2014-01-16 Trustees Of Tufts College Silk powder compaction for production of constructs with high mechanical strength and stiffness
US9505749B2 (en) 2012-08-29 2016-11-29 Amgen Inc. Quinazolinone compounds and derivatives thereof
US9394257B2 (en) 2012-10-16 2016-07-19 Tolero Pharmaceuticals, Inc. PKM2 modulators and methods for their use
CN102887851B (zh) * 2012-11-02 2014-03-19 天津希恩思生化科技有限公司 化合物3,5-二甲基-1h-吡咯-2,4-二甲醛及其制备方法
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
ES2738493T3 (es) 2013-03-14 2020-01-23 Tolero Pharmaceuticals Inc Inhibidores de JAK2 y ALK2 y métodos para su uso
ES2935659T3 (es) 2013-03-15 2023-03-09 Tufts College Composiciones de seda de bajo peso molecular y composiciones de seda estabilizadoras
US11376329B2 (en) 2013-03-15 2022-07-05 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
US10285702B2 (en) 2013-04-24 2019-05-14 Trustees Of Tufts College Bioresorbable biopolymer anastomosis devices
WO2015051304A1 (en) 2013-10-04 2015-04-09 Aptose Biosciences Inc. Compositions, biomarkers and their use in treatment of cancer
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
CA2930359C (en) 2013-12-06 2022-03-01 Novartis Ag Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
WO2015149720A1 (en) 2014-04-04 2015-10-08 Crown Bioscience, Inc.(Taicang) Hnf4g-rspo2 fusion gene and use thereof in treatment of cancer
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
KR20160149256A (ko) 2014-04-30 2016-12-27 화이자 인코포레이티드 시클로알킬-결합된 디헤테로사이클 유도체
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
EP3473271B1 (en) 2014-07-31 2022-07-20 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Human monoclonal antibodies against epha4 and their use
WO2016100721A1 (en) 2014-12-17 2016-06-23 Tufts University Injectable, flexible hydroxyapatite-silk foams for osteochondral and dental repair
EP3233829B1 (en) 2014-12-18 2019-08-14 Pfizer Inc Pyrimidine and triazine derivatives and their use as axl inhibitors
ES2887474T3 (es) 2015-01-08 2021-12-22 Univ Leland Stanford Junior Factores y células que proporcionan inducción de hueso, médula ósea y cartílago
HK1251655A1 (zh) 2015-04-20 2019-02-01 Tolero Pharmaceuticals, Inc. 通过线粒体分析预测对阿伏西地的应答
CN107709344B (zh) 2015-05-01 2022-07-15 共晶制药股份有限公司 用于治疗黄病毒科病毒和癌症的核苷类似物
EP4086264B1 (en) 2015-05-18 2023-10-25 Sumitomo Pharma Oncology, Inc. Alvocidib prodrugs having increased bioavailability
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
EP3865101A1 (en) 2015-07-20 2021-08-18 Tufts University Biodegradable silk ear tubes
US10568887B2 (en) 2015-08-03 2020-02-25 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
CN108472289A (zh) 2015-11-02 2018-08-31 诺华股份有限公司 磷脂酰肌醇3-激酶抑制剂的给药方案
WO2017096165A1 (en) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
US10864299B2 (en) 2016-04-29 2020-12-15 Trustees Of Tufts College Artificial silk based innervated cornea
US11298443B2 (en) 2016-07-01 2022-04-12 Trustees Of Tufts College Innervated artificial skin
WO2018026853A1 (en) 2016-08-01 2018-02-08 Trustees Of Tufts College Biomimetic mechanical tension driven fabrication of nanofibrillar architecture
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
MX2019007332A (es) 2016-12-19 2019-11-18 Tolero Pharmaceuticals Inc Péptidos indicadores y métodos para caracterizar sensibilidad.
EA201991528A1 (ru) 2016-12-22 2020-01-16 Эмджен Инк. БЕНЗИЗОТИАЗОЛЬНЫЕ, ИЗОТИАЗОЛО[3,4-b]ПИРИДИНОВЫЕ, ХИНАЗОЛИНОВЫЕ, ФТАЛАЗИНОВЫЕ, ПИРИДО[2,3-d]ПИРИДАЗИНОВЫЕ И ПИРИДО[2,3-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ G12C KRAS ДЛЯ ЛЕЧЕНИЯ РАКА ЛЕГКОГО, РАКА ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ ИЛИ КОЛОРЕКТАЛЬНОГО РАКА
US20200000713A1 (en) 2017-01-20 2020-01-02 Massachusetts Institute Of Technology Injectable polymer micro-depots for controlled local drug delivery
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
ES2985118T3 (es) 2017-09-08 2024-11-04 Amgen Inc Inhibidores de KRAS G12C y métodos de uso de los mismos
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
WO2019075367A1 (en) 2017-10-13 2019-04-18 Tolero Pharmaceuticals, Inc. PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
WO2019089567A1 (en) 2017-10-30 2019-05-09 Massachusetts Institute Of Technology Layer-by-layer nanoparticles for cytokine therapy in cancer treatment
WO2019094702A1 (en) 2017-11-10 2019-05-16 Cocoon Biotech Inc. Ocular applications of silk-based products
CA3099118A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
EP3788038B1 (en) 2018-05-04 2023-10-11 Amgen Inc. Kras g12c inhibitors and methods of using the same
MA52564A (fr) 2018-05-10 2021-03-17 Amgen Inc Inhibiteurs de kras g12c pour le traitement du cancer
MX2020012731A (es) 2018-06-01 2021-02-22 Amgen Inc Inhibidores de kras g12c y metodos para su uso.
EP4268898A3 (en) 2018-06-11 2024-01-17 Amgen Inc. Kras g12c inhibitors for treating cancer
EP3807276B1 (en) 2018-06-12 2025-12-10 Amgen Inc. Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
US11040038B2 (en) 2018-07-26 2021-06-22 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7454572B2 (ja) 2018-11-19 2024-03-22 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
AU2019391097B2 (en) 2018-12-04 2025-07-03 Sumitomo Pharma America, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US12441736B2 (en) 2018-12-20 2025-10-14 Amgen Inc. KIF18A inhibitors
MX419368B (es) 2018-12-20 2025-01-14 Amgen Inc Heteroarilamidas utiles como inhibidores de kif18a
KR102875569B1 (ko) 2018-12-20 2025-10-23 암젠 인크 Kif18a 억제제
US12459932B2 (en) 2018-12-20 2025-11-04 Amgen Inc. KIF18A inhibitors
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
EP3930845A1 (en) 2019-03-01 2022-01-05 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
EP3941463A1 (en) 2019-03-22 2022-01-26 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
KR20250159270A (ko) 2019-05-21 2025-11-10 암젠 인크 고체 상태 형태
WO2021002984A1 (en) 2019-05-30 2021-01-07 Massachusetts Institute Of Technology Peptide nucleic acid functionalized hydrogel microneedles for sampling and detection of interstitial fluid nucleic acids
WO2020247594A1 (en) 2019-06-04 2020-12-10 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
EP4007752B1 (en) 2019-08-02 2025-09-24 Amgen Inc. Kif18a inhibitors
WO2021026099A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026100A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Pyridine derivatives as kif18a inhibitors
WO2021026101A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
MX2022004656A (es) 2019-10-24 2022-05-25 Amgen Inc Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
CN114901366A (zh) 2019-11-04 2022-08-12 锐新医药公司 Ras抑制剂
KR20220109408A (ko) 2019-11-04 2022-08-04 레볼루션 메디슨즈, 인크. Ras 억제제
PH12022550988A1 (en) 2019-11-04 2023-10-09 Revolution Medicines Inc Ras inhibitors
WO2021092115A1 (en) 2019-11-08 2021-05-14 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
CA3161156A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
AR120457A1 (es) 2019-11-14 2022-02-16 Amgen Inc Síntesis mejorada del compuesto inhibidor de g12c de kras
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021142026A1 (en) 2020-01-07 2021-07-15 Revolution Medicines, Inc. Shp2 inhibitor dosing and methods of treating cancer
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof
MX2022016355A (es) 2020-06-18 2023-04-03 Revolution Medicines Inc Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras.
CA3187757A1 (en) 2020-09-03 2022-03-24 Ethan AHLER Use of sos1 inhibitors to treat malignancies with shp2 mutations
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
CN112661639A (zh) * 2020-12-07 2021-04-16 浙江工业大学 一种4-乙酰丁酸酯类化合物合成方法
AU2021409816A1 (en) 2020-12-22 2023-07-06 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
US12161693B2 (en) 2021-04-14 2024-12-10 Cocoon Biotech Inc. Methods of making stable silk fibroin formulations
AR125787A1 (es) 2021-05-05 2023-08-16 Revolution Medicines Inc Inhibidores de ras
AR125782A1 (es) 2021-05-05 2023-08-16 Revolution Medicines Inc Inhibidores de ras
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
KR20240115979A (ko) 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도
CN119212994A (zh) 2021-12-17 2024-12-27 建新公司 作为shp2抑制剂的吡唑并吡嗪化合物
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
JP2025509217A (ja) 2022-03-07 2025-04-11 アムジエン・インコーポレーテツド ４－メチル－２－プロパン－２－イル－ピリジン－３－カルボニトリルを調製するための方法
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
US20230399313A1 (en) * 2022-06-10 2023-12-14 Advenchen Pharmaceuticals, LLC Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers
CN120504682A (zh) 2022-06-10 2025-08-19 锐新医药公司 大环ras抑制剂
JP2025536257A (ja) 2022-10-14 2025-11-05 ブラック ダイアモンド セラピューティクス，インコーポレイティド イソキノリンまたは６－ａｚａ－キノリン誘導体を使用してがんを治療する方法
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
KR20260005904A (ko) 2023-04-07 2026-01-12 레볼루션 메디슨즈, 인크. 매크로사이클릭 ras 억제제
CN121263418A (zh) 2023-04-07 2026-01-02 锐新医药公司 大环ras抑制剂
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
TW202448897A (zh) 2023-04-14 2024-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
TW202542151A (zh) 2023-12-22 2025-11-01 美商銳格醫藥有限公司 Ｓｏｓ１抑制劑及其用途
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3308134A (en) 1965-10-22 1967-03-07 Mcneilab Inc Spiro(indan-2, 3'-indoline)-1, 2'-diones
US3859693A (en) 1973-06-12 1975-01-14 Charles P Breed Sliding snap shackle
US4002749A (en) 1975-08-12 1977-01-11 E. R. Squibb & Sons, Inc. Substituted indolinones
US4053613A (en) 1975-09-17 1977-10-11 E. R. Squibb & Sons, Inc. 1,3,thiazolinyl and 1,3 thiazinyl substituted indolinones
US4966849A (en) 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
CA1284681C (en) 1986-07-09 1991-06-04 Alcan International Limited Methods and apparatus for the detection and correction of roll eccentricity in rolling mills
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
GB9004483D0 (en) 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
ES2064101T3 (es) 1990-04-02 1995-01-16 Pfizer Compuestos de acido bencilfosfonico inhibidores de la quinasa de tirosina.
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
WO1992007830A2 (en) 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
CA2108889A1 (en) 1991-05-29 1992-11-30 Robert Lee Dow Tricyclic polyhydroxylic tyrosine kinase inhibitors
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
AU668180B2 (en) 1992-05-20 1996-04-26 Merck & Co., Inc. 17-ethers and thioethers of 4-aza-steroids
RU2155187C2 (ru) 1992-08-06 2000-08-27 Варнер-Ламберт Компани Производные индола, их таутомеры, смеси их изомеров или отдельные изомеры и фармацевтически приемлемые соли, фармацевтическая композиция с антиопухолевой или ингибирующей протеин-тирозинкиназу активностью и способ торможения зависящего от протеин-тирозинкиназы заболевания или борьбы с аберрантным ростом клеток млекопитающего или человека.
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
DE69233803D1 (de) 1992-10-28 2011-03-31 Genentech Inc Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9423997D0 (en) * 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5786488A (en) 1996-11-13 1998-07-28 Sugen, Inc. Synthetic methods for the preparation of indolyquinones
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
CA2263838A1 (en) * 1996-08-21 1998-02-26 Sugen, Inc. Crystal structures of a protein tyrosine kinase
DE69734521T9 (de) * 1996-08-23 2006-12-07 Sugen, Inc., South San Francisco Kombinatorische indolinonbibliotheken und verwandte produkte und verfahren zur behandlung von erkrankungen
WO1998024432A2 (en) 1996-12-05 1998-06-11 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
JP4713698B2 (ja) * 1997-03-05 2011-06-29 スージェン， インク． 疎水性薬剤の処方
WO1998045708A1 (en) 1997-04-08 1998-10-15 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
EP0984930B1 (en) * 1997-05-07 2005-04-06 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
WO1998056376A1 (en) 1997-06-13 1998-12-17 Sugen, Inc. Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
EP1066257A2 (en) 1998-03-26 2001-01-10 Sugen, Inc. Heterocylic classes of compounds for the modulating tyrosine protein kinase
HUP0103617A2 (hu) * 1998-05-29 2002-02-28 Sugen, Inc. Protein kinázt gátló, pirrolilcsoporttal helyettesített 2-indolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása

Also Published As

Publication number Publication date
NO20005916L (no) 2001-01-29
US20030105151A1 (en) 2003-06-05
JP4528440B2 (ja) 2010-08-18
AU759226B2 (en) 2003-04-10
AU4410299A (en) 1999-12-13
US7119090B2 (en) 2006-10-10
AR018408A1 (es) 2001-11-14
SK287132B6 (sk) 2009-12-07
NO318083B1 (no) 2005-01-31
IL139934A (en) 2007-10-31
EA005032B1 (ru) 2004-10-28
PL344477A1 (en) 2001-11-05
EP1082305A4 (en) 2001-09-26
ES2429573T3 (es) 2013-11-15
PT2020408E (pt) 2013-09-13
JP2002516310A (ja) 2002-06-04
HK1126770A1 (en) 2009-09-11
EP1082305A1 (en) 2001-03-14
EP2020408B1 (en) 2013-06-26
WO1999061422A1 (en) 1999-12-02
KR20010083039A (ko) 2001-08-31
NO20005916D0 (no) 2000-11-22
HUP0103617A2 (hu) 2002-02-28
TWI229073B (en) 2005-03-11
CO5031249A1 (es) 2001-04-27
CA2314156A1 (en) 1999-12-02
DK2020408T3 (da) 2013-09-30
CN1311775A (zh) 2001-09-05
EP2020408A1 (en) 2009-02-04
SK18062000A3 (sk) 2001-06-11
CN1250526C (zh) 2006-04-12
EA200001258A1 (ru) 2001-08-27
US6395734B1 (en) 2002-05-28
KR100743287B1 (ko) 2007-07-26
NZ508815A (en) 2005-02-25
TR200003514T2 (tr) 2002-05-21
BR9910792A (pt) 2002-01-29
CA2314156C (en) 2010-05-25

Similar Documents

Publication Publication Date Title
IL139934A0 (en) Pyrrole substituted 2-indolinone derivatives and pharmaceutical compositions containing the same
IL139479A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
IL138899A0 (en) Amidene derivatives and pharmaceutical compositions containing the same
IL140862A (en) Thiobenzimidazole derivatives and pharmaceutical compositions containing the same
IL148517A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
IL150077A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
IL144977A0 (en) Pyrrolotriazine derivatives and pharmaceutical compositions containing the same
IL143920A0 (en) 3-heteroarylidenyl-2-indolinone derivatives and pharmaceutical compositions containing the same
HUP0103406A3 (en) 1h-imidazopyridine derivatives and pharmaceutical compositions thereof
IL142665A0 (en) Acyl dipeptidyl derivatives and pharmaceutical compositions containing the same
IL149883A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
IL138573A0 (en) Amide derivatives and pharmaceutical compositions containing the same
IL145428A0 (en) Alkanoyl-substituted heterocyclic derivatives and pharmaceutical compositions containing the same
IL120699A0 (en) Indole derivatives and pharmaceutical compositions containing them
HUP0400887A3 (en) Glycopeptide derivatives and pharmaceutical compositions containing the same
HUP0102990A3 (en) Tetrahydroimidazo-naphtyridine derivatives and pharmaceutical compositions thereof
IL143802A0 (en) Imidazole derivatives and pharmaceutical compositions containing the same
HUP0101381A3 (en) Benzofurylpyrone derivatives and pharmaceutical compositions containing them
PT1466615E (pt) Composição farmacêutica
IL138572A0 (en) Benzoate derivatives and pharmaceutical compositions containing the same
PL343769A1 (en) Pharmaceutical composition
IL147214A0 (en) 1-methylcarbapenem derivatives and pharmaceutical compositions containing the same
IL141080A0 (en) Disubstituted maleimide derivatives and pharmaceutical compositions containing the same
HUP0100680A3 (en) Indole derivatives and medicinal compositions containing the same
HUP0103203A3 (en) Azaadamantane derivatives and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
FF Patent granted